In a trial involving patients with relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to significantly longer event-free survival than standard salvage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback